VentiRx Pharmaceuticals, the San Diego and Seattle-based drug developer, said today its experimental treatment for cancer passed its initial clinical trial in 33 patients. The drug, VTX-2337, was found to be safe and well-tolerated in the study and showed increasing signs of activity as doses escalated, the company said. The drug is designed to stimulate the innate immune system to fight tumors, in tandem with standard cancer treatments, VentiRx said. The company plans to take the next step, with a Phase Ia/2b trial, “in the near future,” according to a statement.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
